‘Made in Spain’ tuberculosis vaccine receives European support in its latest phase

The urgent need during the Covid pandemic created barriers to prevention, which meant a significant reduction in the number of people requiring treatment, especially for multidrug-resistant TB . WHO estimates that only two in five people with multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB are currently receiving treatment.